The innovative vaccine shows promising against pancreas and large intestine fueled by karst

The new anti -cancer vaccine, which stimulates the immune system to direct one of the most common cancer mutations, showed early results in patients with pancreatic and large intestine, two of the most difficult cancer for the treatment of cancer, according to the study conducted partly by researchers at the comprehensive center of Cancer Ucla Health Jonson.

Discoveries, published, show that the vaccine, called ELI-002 2P, can cause powerful and permanent immune answers and can help prevent or delay cancer recurrence in high-risk patients whose tumors are powered by Kras mutations. After the extended observation of 19.7 months, scientists found that the median survival free from relapses was 16.33 months, and the general survival median was 28.94 months, but exceeding historical norms-with the greatest benefit in patients who developed strong reactions of T cells specific to MKRAS. For example, the median survival free from relapses was not achieved compared to 3.02 months, and the median of complete survival was not achieved compared to 15.98 months comparing the above threshold groups of T.

“This is an exciting progress for patients with dwarf driven cancer, especially pancreatic cancer, where the recurrence after standard treatment is almost given, and effective therapies are limited,” said the first author of the ZEV Wainberg, MD study, Medicine compensation at David Geffen School of Medicine in Ucla and UCLACZ in UCLA HEALTH JERSON CANCER CANCER. “We noticed that patients who developed strong immune answers to the vaccine, remained free of illness and survived much longer than expected.”

The study, which included supplementary data from the Amplify 201 Phase 1 study, assessed security and effectiveness Vaccinations targeted at lymph nodes, which are focused on Kras mutations. These mutations occur in about 25% of solid tumors and drive about 90% of pancreatic cancer and 50% colorectal cancer.

Unlike some other methods of treating cancer, which may require personalization for each patient based on its specific features and mutations, ELI-002 2P is a “unusual” vaccine, which has been designed as a standardized product that can stimulate the immune system for recognizing and attacking cancer cells in a general way, without the need for the need for time and the need for need unique vaccine.

In the study, 25 patients with pancreas (20) or colorectal cancer (5), who underwent surgery and showed signs of minimal residual disease or traces of DNA cancer in the blood, which often signals a recurrence.

Each patient received a series of injections from ELI-002 2P, which uses amphifilic technology developed by Elicio Therapeutics, which helps the antigens transfers directly to the lymph nodes, in which immunological answers are activated.

Among the findings:

• 84% of patients (21 out of 25) generated specific to kras Cells T.including both CD4+auxiliary cells and CD8+deadly cells. Importantly, many of these T cells remained over time.
• In 24% of patients (3 pancreas, 3 large intestine) biomarkers associated with the tumor were completely cleaned.
• Patients with higher (above the threshold) Tar response T were a longer survival free of recurrence compared to patients with lower tns answers T. In patients with higher answers, a median survival free of relapses was not achieved, which means that so many patients were still not free from cancer, it was impossible to calculate the median time to recurrence, compared to 3,02 months (p = p = p = 0.0002) in patients with lower answers, and the median of total survival was not achieved compared to 15.98 months (p = 0.0099) among people without strong cell reactions.
• 67% of the patients studied developed an immune response to additional cancer mutations, which suggests the potential of wider anti -cancer activity.

Aiming at kras has long been considered one of the difficult challenges in anti -cancer therapy. This study shows that the ELI-002 2P vaccine can safely and effectively train the immune system to recognize and fight cancer mutations. It offers a promising approach to generating precise and lasting immune answers without complexity or cost of fully personalized vaccines. “

Zev Wainberg, MD, Professor of Medicine, David Geffen School of Medicine in Ucla

The research team has completed registration in a larger study of the ELI-002 7P phase, a new generation vaccine version, which is focused on a wider set of kras mutations.

Older authors of the study are Shubham Pant with MD Anderson Cancer Center and Eileen O’Reilly from Memorial Sloan Kettering Cancer Center. The full list of authors can be found in the study.

The study was sponsored and financed by Elicio Therapeutics.